Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgomAb Therapeutics NVAGMB +1.96%14 EV-to-EBITDA is -9.91 as of Aug. 27, 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 414 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 241545.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AgomAb Therapeutics NV's enterprise value is $414.31 Mil.
AgomAb Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-41.82 Mil. Therefore, AgomAb Therapeutics NV's EV-to-EBITDA for today is -9.91.
The historical rank and industry rank for AgomAb Therapeutics NV's EV-to-EBITDA or its related term are showing as below:
AGMB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.17 Med: 0 Max: 0
Current: -9.91
AGMB's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.54
vs AGMB: -9.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AgomAb Therapeutics NV's PE Ratio (TTM) for today is calculated as:
AgomAb Therapeutics NV's share price for today is $14.30.
AgomAb Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.858.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AgomAb Therapeutics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's EV-to-EBITDA falls into.
AgomAb Therapeutics NV's current Enterprise Value is $414.31 Mil.
AgomAb Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV (AGMB) has a EV-to-EBITDA of -9.91 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AgomAb Therapeutics NV. According to the industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 414 companies in the Biotechnology industry.
Is AgomAb Therapeutics NV's EV-to-EBITDA too high?
AgomAb Therapeutics NV's current EV-to-EBITDA is -9.91. Based on the distribution chart, AgomAb Therapeutics NV ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's EV-to-EBITDA compare to CRMD and RGNX?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 414 companies for EV-to-EBITDA. This places AgomAb Therapeutics NV in the lower half of its industry. The industry median EV-to-EBITDA is 13.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.54, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AgomAb Therapeutics NV. For the Biotechnology industry, the median EV-to-EBITDA is 13.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current EV-to-EBITDA is -9.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current EV-to-EBITDA of -9.91. The current EV-to-EBITDA is -9.91. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current EV-to-EBITDA is -9.91 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 
